ARTICLE | Product Development

Chinks in the armor

What’s next for Celgene in light of mongersen failure, Otezla underperformance

October 28, 2017 4:00 AM UTC
One of those was Celgene’s own pomalidomide, which received accelerated approval from FDA in 2013 and was one of only two new product launches by Celgene between 2012 and this year.

Even with slowing revenues tied largely to a single product and a dearth of launches, Wall Street darling Celgene Corp. had been on an extended tear, growing its share price in excess of 300% since the beginning of 2012.

Clinical and commercial disappointments revealed within a one-week period revealed an unexpected weakness, and will see Celgene Corp. relying more heavily on ozanimod for near-term growth, while drivers of mid- to long-term growth are less certain...

BCIQ Company Profiles

Celgene Corp.